Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative PDT with Pentalafen in Glioblastoma
2025-520563-41-00Phase 2Authorised
- Sponsor
- Hemerion Therapeutics
- Start
- Jun 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pentalafen in glioblastoma (GBM) and glioma, sponsored by Hemerion Therapeutics. Primary endpoint: Maximum tolerated dose (MTD). Planned start Jun 2025; status: authorised.
02
Drugs
pentalafen
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on 2025-520563-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520563-41-00.